Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate 05:35:04 2024-04-15 am EDT 5-day change 1st Jan Change
8.622 EUR +0.56% Intraday chart for Grifols, S.A. -8.17% -44.03%
This Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Grifols to Add Independent Directors in Audit, Compensation Committees to Improve Governance MT
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper RE
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT
GRIFOLS : Factoring in a more moderate earnings recovery; long-term view intact Alphavalue
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake RE
Grifols Expects H1 Completion of Shanghai RAAS Stake Sale to Haier MT
Grifols Plans to Issue Senior Secured Notes MT
Global markets live: ASML, Walt Disney, McDonald's, Goldman Sachs, Apple... Our Logo
Spanish Drugmaker Grifols Issues Clarification to Watchdog on Previous EBITDA Calculations MT
Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor RE
Grifols Says Procleix ArboPlex Assay Receives EU's CE Mark on Safety for Blood Screening MT
Grifols’ Nucleic Acid Test for Arbovirus Detection Gets CE Marking MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday MT
European Equities Close Mixed in Friday Trading; UK Regulator Probes Vodafone, Three UK Proposed Merger MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading MT
Grifols' Financial Reports Have No Major Accounting Mistakes, Spanish Regulator Says MT
Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Ahead of Powell Speech MT
European shares set for weekly gains; UK's Phoenix soars RE
U.S. Futures Flat, European Stocks Mixed DJ
Spanish Securities Regulator Finds No Significant Errors in Grifols' Financial Reports MT
Chart Grifols, S.A.
More charts
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
8.574 EUR
Average target price
18.43 EUR
Spread / Average Target
+114.95%
Consensus
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. News Grifols, S.A.
  5. Grifols: Q4 in line; today’s adverse market reaction means a buying opportunity